# Gilead Sciences, Inc.  Share Price Target ‘$81.93’, now 19.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.share-price-target-81.93-now-19.2-upside-potential/4121164748
- Published: 2024-07-12T14:02:06+01:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** with ticker code (GILD) have now 26 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The target price
High/Low ranges between $119.00 and $67.00 calculating the average target share 
price we see $81.93. (at the time of writing). Given that the stocks previous close
was at $68.75 this is indicating there is a potential upside of 19.2%. The 50 day
MA is $66.34 and the 200 moving average now moves to $73.59. The market capitalization
for the company is 87.17B. The current share price for the company is: $69.97 USD

 The potential market cap would be $103,883,818,327 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 194.36, revenue per share of $22.00
and a 10.5% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: